Singapore eDevelopment Ltd (“SeD”), through its subsidiary Global
BioLife Inc. (“Global BioLife”), has initiated advanced research of a
new universal therapeutic drug platform, known as Linebacker, to combat a
range of diseases including Alzheimer’s, diabetes and cancer. The
research will be led by two-time Nobel Prize nominee, Mr Daryl Thompson.
Singapore Exchange-listed SeD said Mr Daryl Thompson will leverage on
his expertise in organic and carbohydrate chemistry and the use of
pandemic technology in combating the Ebola virus in the research and
development of this universal therapeutic drug platform, known as
Linebacker.
Unlike the traditional approach to cure individual diseases with
specific drugs, the Linebacker platform seeks to offer a breakthrough
option for multiple diseases to be cured. It can also potentially combat
drug-resistant viruses and antibiotic-resistant bacteria.
Mr Daryl Thompson will lead the research to be conducted by Global
BioLife in his capacity as Director of Scientific Initiatives. Global
BioLife is an 80%-held subsidiary of SeD’s wholly-owned subsidiary,
Global BioMedical Inc. The remaining stake of Global BioLife is held in
equal proportions by Mr Daryl Thompson’s GRDG Sciences LLC and Australia
Securities Exchange-listed Holista CollTech Limited.
Mr Daryl Thompson was nominated for a Nobel Prize in 2015 and 2016
for his research in cutting-edge organic and carbohydrate chemistry as
well his research in pandemics technology to fight pandemics such as
Ebola. He has used his expertise to initiate research regarding
universal therapeutics to cure the world’s deadliest diseases. Mr Scott
Truesdell, Research Coordinator and Special Projects Leader at Global
BioLife, will execute the research on the Linebacker platform.
No comments:
Post a Comment